Lv1
90 积分 2025-07-12 加入
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management
15天前
已关闭
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management
17天前
已关闭
Heart-liver co-management in MASLD: from concept to clinical practice
21天前
已完结
Resolving Metabolic Dysfunction-Associated Steatotic Liver Disease Reduces Subclinical Cardiovascular Damage in Chinese Youths
23天前
已完结
Combined Impact of Triglyceride-Glucose Index and Alanine Aminotransferase on Steatotic Liver Disease and Subtypes
5个月前
已完结
Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs
8个月前
已完结
Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons
8个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
11个月前
已完结
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
11个月前
已完结
Clinical Trial Landscape in NASH
11个月前
已完结
皖公网安备34019202002308
